Insider Trading Report: January 14, 2026 — 5 Purchases, 1 Sale Across 10 Companies
Overview
On January 14, 2026, insiders reported 21 transactions totaling $819K across 10 unique tickers, according to verified public filings. The standout activity was 5 purchases versus just 1 sale, highlighting potential insider confidence in several companies amid a total of 21 filings.
Purchases dominated with a combined value exceeding $637K, led by high-profile buys from CEOs and directors. This contrasts with the single sale of $35K, which may reflect routine diversification rather than broader concerns. Secondary transactions, including awards and minor activity, filled out the rest, but purchases remain the key signal.
News coverage was robust with 19 articles across the tickers, particularly for IMRX (5 articles) and CTBI (though mostly technical crosses).
Primary Insider Transactions (Purchases & Sales)
Purchases and sales represent the most meaningful insider signals, as they reflect executives and directors directly putting their own money at risk or reducing exposure. With 5 buys and 1 sell this reporting date, the balance tilts toward optimism.
| Ticker | Insider | Title | Type | Value | Shares | Price | Market Cap | Filing Date |
|---|---|---|---|---|---|---|---|---|
| ASST | Cole Matthew Ryan | director, officer: Chief Execu | 🟢 Purchase | $459K | 500,000 | $0.92 | N/A | 2026-01-14 |
| IMRX | Feinberg Peter | director | 🟢 Purchase | $87K | 20,000 | $4.35 | N/A | 2026-01-14 |
| GLSI | Patel Snehal | director, 10 percent owner, of | 🟢 Purchase | $80K | 2,900 | $27.54 | N/A | 2026-01-14 |
| PFBX | Stilwell Joseph | 10 percent owner | 🟢 Purchase | $6K | 300 | $20.50 | N/A | 2026-01-14 |
| CMTV | Baker Bruce D | director | 🟢 Purchase | $5K | 180 | $28.00 | N/A | 2026-01-14 |
| TRT | TING HOCK MING | director | 🔴 Sale | $35K | 5,000 | $7.08 | N/A | 2026-01-14 |
The purchases signal strong insider confidence, especially ASST's CEO Cole Matthew Ryan acquiring 500,000 shares for $459K at a $651M market cap company—by far the largest move. IMRX director Feinberg Peter's $87K buy (20,000 shares, $150M cap) and GLSI CEO/CFO Patel's $80K purchase (2,900 shares, $402M cap) further underscore leadership betting on upside. Smaller buys at PFBX ($6K by 10% owner) and CMTV ($5K by director) add to the bullish tone. The lone TRT sale ($35K by director at $58M cap) is modest and could indicate personal diversification rather than alarm, given its size relative to the buys. Recent news provides context: ASST announced a major acquisition approval, IMRX shared positive trial data despite stock dips, and GLSI noted CEO buying alongside peer comparisons.
Other Transactions (Awards, Options, etc.)
Secondary transactions included 11 others and 4 awards, typically less indicative of directional bets as they often involve compensation, options exercises, or zero-value adjustments. PBSV saw four $11K director awards, while TSBK had multiple officer filings totaling $103K, mostly from risk and credit executives.
| Ticker | Insider | Type | Value | Filing Date |
|---|---|---|---|---|
| PBSV | Perlysky Dov | Award | $11K | 2026-01-14 |
| PBSV | MICHEL KIRK WHEELER | Award | $11K | 2026-01-14 |
| PBSV | WIESEN IRVING L | Award | $11K | 2026-01-14 |
| PBSV | SPINDEL HOWARD | Award | $11K | 2026-01-14 |
| TSBK | Seath Matthew Douglas | $28K | 2026-01-14 |
Recent News
[ASST] (Strive, Inc.)
- Strive, Inc. (Nasdaq: ASST) and Semler Scientific (Nasdaq: SMLR) Announce Shareholder Approval for Acquisition of Semler Scientific (globenewswire.com)
- Strive, Inc. (NASDAQ:ASST) Short Interest Update (defenseworld.net)
[IMRX] (Immuneering)
- Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (seekingalpha.com)
- Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower (benzinga.com)
- Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript (seekingalpha.com)
- Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (globenewswire.com)
[GLSI] (Greenwich LifeSciences)
- Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,300 Shares (defenseworld.net)
- Head-To-Head Analysis: Greenwich LifeSciences (NASDAQ:GLSI) vs. Avalon GloboCare (NASDAQ:ALBT) (defenseworld.net)
[PFBX]
No recent headlines available.
[CMTV] (Community Bancorp.)
- Regional Banks Show Resilience Amid High Rates & Credit Gains (zacks.com)
- Community Bancorp. Announces Application to Uplist to Nasdaq Capital Market (accessnewswire.com)
[TRT]
No recent headlines available.
What This Means
Insider purchases often signal confidence in a company's prospects, as executives use personal funds to increase stakes—here, 5 buys dwarfing 1 sale across small- to mid-cap names like ASST ($651M) and IMRX ($150M). Sales warrant scrutiny but context matters: TRT's $35K director sale is small and isolated, potentially routine rather than a red flag.
Use this data as one research tool alongside fundamentals, technicals, and news—not a standalone signal. Insiders trade for diverse reasons like taxes, gifting, or hedging, so clusters (e.g., CEO buys) carry more weight than singles.
This report is informational only. Always cross-verify filings and consult professionals.
Independent, data-driven market research.
No hype. No promotions. Zero bias. Just experimental insights from EverHint.
This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
Support the project by liking, sharing, or subscribing — it helps more readers discover these signals. 📊🙏